AstraZeneca PLC

Latest AstraZeneca PLC News and Updates

  • Vials of AstraZeneca COVID-19 vaccine
    Healthcare

    AstraZeneca COVID-19 Vaccine Originated in the U.K., Is Used Globally

    According to a recent study, a booster dose of AstraZeneca works against the omicron variant. What's the AstraZeneca vaccine’s country of origin?
    By Anuradha Garg
  • Pharmacist preparing COVID-19 vaccine shot
    News

    AstraZeneca Will Profit From Its COVID-19 Vaccine—Why It Matters

    AstraZeneca plans to profit off its COVID-19 vaccine. Here's what that means and why it matters.
    By Rachel Curry
  • AstraZeneca scientist
    Healthcare

    Will the FDA Approve AstraZeneca's COVID-19 Cocktail?

    AstraZeneca's COVID-19 vaccine never received emergency-use authorization in the U.S. Will the FDA approve its antibody cocktail?
    By Rachel Curry
  • AstraZeneca vaccine syringes
    Healthcare

    Is the AstraZeneca Vaccine Approved in the U.S.?

    The AstraZeneca COVID-19 vaccine hasn't been approved in the U.S. but it might get approved by early April.
    By Kathryn Underwood
  • best vaccine stock to buy
    Healthcare

    Best COVID-19 Vaccine Stocks to Buy Now for 2021

    The COVID-19 vaccine race isn’t over. What are the best COVID-19 vaccine stocks for investors to buy now for 2021? What can investors expect in the next year?
    By Ambrish Shah
  • is astrazeneca an american company
    Company & Industry Overviews

    U.K. Government Approves AstraZeneca's Coronavirus Vaccine

    AstraZeneca is a U.K.-based company. The U.K. government approved AstraZeneca's COVID-19 vaccine. How will the vaccine impact the fight against COVID-19?
    By Kori Williams
  • astrazen main
    Healthcare

    How to Get Help With Your Prescriptions With AstraZeneca Patient Assistance

    You may not even realize it, but you may be eligible to save money on AstraZeneca prescriptions from the AZ&Me prescription savings program.
    By Rachel Curry
  • Alexion Acquisition AstraZeneca
    Healthcare

    AstraZeneca to Acquire Alexion for $39 Billion, Stock Down

    On Dec. 12, AstraZeneca agreed to acquire Alexion for $39 billion. The deal would bolster AstraZeneca’s footprint in rare diseases.
    By Ambrish Shah
  • is astrazeneca a buy
    Financials

    Is AstraZeneca Stock Right for Your Portfolio After Alexion Announcement?

    AstraZeneca stock has lost favor with some investors. The company announced that it plans to purchase Alexion. Is AstraZeneca stock still a buy for some investors?
    By Ruchi Gupta
  • what drugs does astrazeneca make
    Healthcare

    What Drugs Does AstraZeneca Make?

    AstraZeneca is a leading biopharmaceutical company that focuses on developing drugs to treat cancer, heart disease, and COPD. What drugs does the company make?
    By Kathryn Underwood
  • uploads///Article
    Company & Industry Overviews

    How Did AstraZeneca’s CVMD Franchise Perform in 2014?

    In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.

    By Mike Benson
  • uploads///ANR
    Company & Industry Overviews

    Analysts’ Expectations for Sanofi

    According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

    By Mike Benson
  • uploads///INTC
    Fund Managers

    AQR Capital increases stake in Intel

    Intel generated ~$5.7 billion in cash from operations. The company paid quarterly dividends of $1.1 billion and repurchased 122 million shares for $4.2 billion.

    By Diana Key
  • uploads///geon
    Real Estate

    Why AQR Capital exits its position in Geo Group Inc.

    AQR Capital sold a position in GEO Group Inc. in 2Q14. The company accounted for a 0.0206% position in the fund’s first quarter U.S. long portfolio.

    By Patricia Garner
  • uploads///Chart
    Earnings Report

    Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16

    AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

    By Mike Benson
  • astrazeneca
    Healthcare

    AstraZeneca and Other COVID-19 Vaccine Trials Seek Volunteers

    With COVID-19 vaccine trials moving ahead, AstraZeneca and other companies need volunteers.
    By Rachel Curry
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    Key Risks Facing Sucampo Pharmaceuticals in 2017

    Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

    By Kenneth Smith
  • uploads///Total IG Bond Issuance for the Week Ending November
    Company & Industry Overviews

    AstraZeneca Issued High-Grade Bonds to Acquire ZS Pharma

    Last week, AstraZeneca issued A2/A rated high-grade bonds worth $6.0 billion to fund the acquisition of ZS Pharma (ZSPH).

    By Lynn Noah
  • uploads///Novavax RSV Pipeline
    Company & Industry Overviews

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

    By Kenneth Smith
  • uploads///PFE MDVN deal
    Company & Industry Overviews

    What’s the Story behind the Pfizer-Medivation Deal?

    Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s to Be Expected from Novartis’s 3Q16 Earnings?

    Novartis, one of the world’s largest pharmaceutical companies by revenue, is set to release its 3Q16 earnings on October 25, 2016.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s New Oncology Portfolio May See Healthy Growth

    In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.

    By Margaret Patrick
  • uploads///freestocks org  unsplash
    Company & Industry Overviews

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

    By Mike Benson
  • uploads///Neuroscience
    Earnings Report

    Bristol-Myers Squibb’s Neuroscience and Immunoscience Segments

    Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Bristol-Myers Squibb’s Other Segments

    Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

    By Mike Benson
  • Healthcare

    Why AstraZeneca’s oncology pipeline is attractive to Pfizer

    Pfizer (PFE) is seeking to expand its oncology franchise and a combination with AstraZeneca (AZN) would be meaningful due to the latter’s pipeline of cancer drugs.

    By Samantha Nielson
  • uploads///Chart  GSK
    Company & Industry Overviews

    How GlaxoSmithKline Stock Performed in 1Q18

    GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Valuation Report Card: How Did It Score?

    The fundamental factors affecting stock prices and valuation include the performance of growth platforms as well as the exclusivity of blockbuster drugs.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca Is Taking Steps to Improve Its Position in Oncology

    During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

    By Mike Benson
  • uploads///Kisqali BTD
    Company & Industry Overviews

    Novartis Receives 2 Breakthrough Therapy Designations in January

    In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

    By Daniel Collins
  • uploads///Krystexxa
    Company & Industry Overviews

    Introducing Krystexxa, the Latest Addition to Horizon’s Orphan Portfolio

    In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.

    By Jillian Dabney
  • uploads///cancer _
    Company & Industry Overviews

    Tesaro Stock Up over 16% on Rumors of Acquisition by Roche

    Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.

    By Sarah Collins
  • uploads///BYI
    Fund Managers

    AQR Capital initiated position in Bally Technologies Inc.

    AQR Capital initiated a position in Bally Technologies during the third quarter of 2014 that accounts for 0.22% of the fund’s 3Q14 portfolio.

    By Diana Key
  • uploads///Van Eck Video
    Macroeconomic Analysis

    What Are Generic Drugs and Why Are They Important?

    TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]

    By VanEck
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

    Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017

    On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

    By Margaret Patrick
  • uploads///US Investment Grade Bond Fund Flows
    Company & Industry Overviews

    Investment-Grade Bond Funds Saw Outflows in November

    According to Lipper’s funds flow data, investment-grade bond funds saw net outflows of $789.1 million up to the week ending November 25.

    By Lynn Noah
  • uploads///Oncology
    Earnings Report

    AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?

    AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Will Be a Key Driver of Biogen’s Future Valuations?

    Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).

    By Margaret Patrick
  • Real Estate

    Why AQR Capital increased its position in Apple in 2Q14

    AQR Capital increased its position in Apple from 0.86% in the previous quarter to 1.24% in the fund’s second quarter U.S. long portfolio.

    By Patricia Garner
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Key Focus: Oncology

    AstraZeneca’s (AZN) key focus is its oncology segment. The segment’s contribution increased to more than 12% in 1Q16. Its key products include Zoladex, Faslodex, and Iressa.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca May Witness a Fall in 2017 Net Profit Margin

    Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Other Drugs for Non-small Cell Lung Cancer

    Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

    By Mike Benson
  • uploads///inorganic growth
    Company & Industry Overviews

    Four Key Deals: Analyzing Pfizer’s Impending Growth

    Over the past year, Pfizer completed multiple acquisitions to restore its top line growth. They will offset the revenue decline and fuel Pfizer’s top line.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017

    Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    This Could Be a Solid Growth Driver for Myriad Genetics in 2018

    Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Oncology Segment: Another Growth Platform for AstraZeneca?

    The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.

    By Mike Benson
  • uploads///salix
    Company & Industry Overviews

    What Might Have Fueled Valeant’s Interest in Salix?

    The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.

    By Jillian Dabney
  • uploads///Recent wins
    Earnings Report

    Brodalumab, Oral Relistor among Valeant’s Recent Wins

    Valeant’s (VRX) recent wins include the FDA’s advisory committee vote in favor of approving brodalumab for the indication of mild to moderate psoriasis.

    By Jillian Dabney
  • uploads///Chart
    Miscellaneous

    Teva’s Respiratory Drugs Contribute 11% to Specialty Medicines

    Teva’s respiratory drugs franchise provides solutions for asthma, COPD, and allergic rhinitis. Respiratory drugs contributed nearly 11% of total revenues for Teva’s Specialty Medicines in 2014.

    By Mike Benson
  • uploads///gks
    Earnings Report

    How Has Aquinox Performed Compared to Peers?

    Aquinox has a positive future outlook and will likely continue to better its performance in the near future.

    By Gabriel Kane
  • uploads///Chart  NVO
    Miscellaneous

    Performance of Novo Nordisk Stock in 2Q17

    Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb: What Do Its Other Segments Offer?

    Bristol-Myers Squibb’s (BMY) neuroscience segment’s sales declined by 63.0% in 2015 from 2014, while its immunoscience segment’s sales improved ~14.1%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for GlaxoSmithKline in May

    GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.

    By Mike Benson
  • who owns astrazeneca
    Healthcare

    Is AstraZeneca Stock a Good Buy at These Prices?

    AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group. Is AstraZeneca a good stock to buy?
    By Ambrish Shah
  • Company & Industry Overviews

    Financials: Biggest Negative Contributor to PEUGX in 1Q16

    The Putnam Europe Equity Fund – Class A (PEUGX) fell 4.3% in 1Q16, making it a below-average performer among the 12 funds in this review. In the past one year, PEUGX has fallen 7.9%

    By David Ashworth
  • astrazeneca covid vaccine resumes trials
    Healthcare

    AstraZeneca Resumes COVID-19 Clinical Trials in U.K., Stock Up

    AstraZeneca stock rises as the company resumes its COVID-19 vaccine clinical trials in the U.K. after a pause due to safety issues.
    By Ambrish Shah
  • operation warp speed companies
    Healthcare

    Operation Warp Speed Has Invested Billions in Potential COVID-19 Vaccines

    The U.S. government’s Operation Warp Speed program has already invested billions in six potential coronavirus vaccine candidates.
    By Ambrish Shah
  • AstraZeneca Halts COVID-19 Vaccine Study After Unexplained Illness
    News

    AstraZeneca Halts COVID-19 Vaccine Study After Unexplained Illness

    AstraZeneca has halted trials of the Oxford University coronavirus vaccine after a suspected adverse reaction from a participant in the U.K.
    By Mark Pygas
  • uploads///patent cliff top
    Company & Industry Overviews

    Why the Patent Cliff Is a Key Driver of Generic Drug Growth

    Over the last several years, patent cliffs have led to steep revenue losses for traditional pharmaceuticals as well as created a gateway for smaller companies to come to market with generics.

    By VanEck
  • AstraZeneca Secures Deal With Australia for COVID-19 Vaccine
    Healthcare

    AstraZeneca Secures Deal With Australia for COVID-19 Vaccine

    AstraZeneca, a U.K.-based pharmaceutical giant, has secured yet another deal to supply the coronavirus vaccine being developed by Oxford University.
    By Mark Pygas
  • uploads///PD  class action
    Company & Industry Overviews

    Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

    The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Oncology Products Performed in 4Q17

    AstraZeneca’s (AZN) oncology products include legacy oncology products as well as new oncology products.

    By Mike Benson
  • uploads///AZN
    Company & Industry Overviews

    Major Expected Events from AstraZeneca’s R&D in H2 2018

    AstraZeneca has seen major recent product approvals such as Lynparza in Japan for breast cancer and Tagrisso in the EU for lung cancer.

    By Kenneth Smith
  • Company & Industry Overviews

    Alpha Has Eluded PEUGX in One Year to March 15

    Along with a negative information ratio, PEUGX also posted a negative alpha in the one-year period ended March 15, 2016. This placed it tenth among the 12 funds in this review.

    By David Ashworth
  • uploads///laboratory _
    Healthcare

    Pfizer Soars Due to Hopes about a Coronavirus Vaccine

    Pfizer (NYSE:PFE) stock rose 2.4% in pre-market trading at 7:51 AM ET today. The company’s experimental COVID-19 vaccine showed positive results.

    By Ambrish Shah
  • uploads///cost benefit analysis
    Financials

    A Cost-Benefit Analysis of the Brexit Decision

    To understand how the Brexit result stands to impact your portfolio or your willingness to invest in the United Kingdom, a cost-benefit analysis is pertinent.

    By Surbhi Jain
  • uploads///AdobeStock_
    Earnings Report

    AstraZeneca Rises on Its Earnings Beat

    AstraZeneca (AZN) reported its second-quarter earnings results on July 25. The stock is already up 6.39% on the day and is trading close to $42.91.

    By Margaret Patrick
  • uploads///medic _
    Company & Industry Overviews

    AstraZeneca’s Lynparza Continues to Dominate

    In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    Tagrisso: AstraZeneca’s Top-Selling Drug in Q1

    AstraZeneca’s (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.

    By Margaret Patrick
  • uploads///microscope _
    Company & Industry Overviews

    How Are AstraZeneca’s Revenues Trending in 2019?

    On its first-quarter earnings conference call, AstraZeneca (AZN) guided for year-over-year product sales growth in high-single-digit percentage in 2019. The company, however, expects modest product sales growth in the second half of 2019 due to higher oncology revenue in the previous period.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What AstraZeneca Expects for EPS in Fiscal 2019

    In its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for core EPS of $3.50–$3.70 in fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s Oncology Portfolio: Growth Trends in 2019

    During AstraZeneca’s fourth-quarter presentation, it highlighted the potential of Tagrisso to become the highest-earning drug in its portfolio in 2019.

    By Margaret Patrick
  • uploads///ousa chea  unsplash
    Company & Industry Overviews

    What Are Analysts Recommending for PFE and AZN?

    On April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at AstraZeneca’s and Eli Lilly’s Tax and Debt

    In fiscal 2018, AstraZeneca (AZN) and Eli Lilly (LLY) reported effective tax rates of 3% and $15.98%, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?

    In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What’s Expected for AstraZeneca’s or Eli Lilly’s EPS Growth

    In its fourth-quarter earnings investor presentation, AstraZeneca (AZN) guided for core EPS of $3.50–$3.70 in fiscal 2019, expecting robust YoY (year-over-year) product sales growth and productivity improvements.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What are AstraZeneca’s Key Growth Drivers?

    In fiscal 2018, AstraZeneca’s (AZN) revenue fell 2% YoY (year-over-year) to $22.09 billion on a CER (constant-exchange-rate) and reported basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Is AstraZeneca Faring in Chinese Markets?

    In the first nine months of 2018, AstraZeneca (AZN) reported revenues worth $2.85 billion from China, which is a YoY rise of 33% on an actual basis and 27% on a CER (constant exchange rate) basis.

    By Margaret Patrick
  • uploads///AstraZeneca
    Company & Industry Overviews

    Why Has AstraZeneca’s Stock Price Increased in 2018?

    On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.

    By Daniel Collins
  • uploads///Januvia
    Company & Industry Overviews

    A Look at Merck’s Diabetes and Women’s Health Business

    Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.

    By Daniel Collins
  • uploads///Invega
    Company & Industry Overviews

    How JNJ’s Invega Sustenna and Risperdal Consta Performed

    Johnson & Johnson’s (JNJ) Invega Sustenna, Xeplion, Trinza, and Trevicta combined witnessed solid growth in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    A Closer Look at Novartis’s Innovative Medicines Segment

    Novartis’s Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis ADR’s Performance and Revenue Estimates for Q3 2018

    Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.

    By Mike Benson
  • uploads///test _
    Healthcare

    Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018

    On October 2, Johnson & Johnson announced the completion of the divestiture of its LifeScan business to Platinum Equity for ~$2.1 billion.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    A Look at Shire’s Valuation on September 19

    Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.

    By Mike Benson
  • uploads///business _
    Miscellaneous

    Novartis to Divest Portions of Sandoz US to Aurobindo

    Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.

    By Mike Benson
  • uploads///doctor _
    Company & Industry Overviews

    EC Approves GSK’s Nucala for Children with Severe Asthma

    On August 30, GlaxoSmithKline (GSK) announced that the EC approved Nucala for pediatric patients with severe refractory eosinophilic asthma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Sandoz in Q2 2018

    Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.

    By Mike Benson
  • uploads///AZN
    Company & Industry Overviews

    How Did AstraZeneca’s CVRM and Respiratory Products Perform?

    Brilinta’s sales increased by 13.0% to $316.0 million, and Farxiga’s sales grew 34.0% to $340.0 million in the second quarter.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Novartis’s SOLAR-1 Trial Met Primary Endpoint

    Novartis (NVS) announced on August 23 that its SOLAR-1 trial evaluating alpelisib combined with fulvestrant has met its primary endpoint.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Gauging Analysts’ Expectations for Novavax and Peers in August

    Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation, which is the current source of its revenue.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.

    By Mike Benson
  • uploads///Januvia
    Company & Industry Overviews

    How Is Merck’s Diabetes and Women’s Health Business Positioned?

    In the second quarter of 2018, Merck’s (MRK) Januvia and Janumet generated revenues of $949 million and $585.0 million, respectively.

    By Daniel Collins
  • uploads///checklist _
    Earnings Report

    How Baxter International Fared in the Second Quarter

    Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.

    By Kenneth Smith
  • uploads///syringe _
    Earnings Report

    GlaxoSmithKline’s Q2 2018 Earnings: Analysts’ Estimates

    Analysts are estimating that GlaxoSmithKline’s (GSK) revenues will decrease 1.5% to 7.2 billion pounds in Q2 2018.

    By Mike Benson
  • uploads///blood _
    Company & Industry Overviews

    Why Advaxis Stock Is Soaring Today

    Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.

    By Daniel Collins
  • uploads///diabetes
    Company & Industry Overviews

    A Look at Novo Nordisk’s Financial Position

    Novo Nordisk (NVO) reported Q1 2018 revenues of 26.9 billion Danish kroner, compared to 28.5 billion Danish kroner in Q1 2017—down ~5% YoY.

    By Daniel Collins
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.